Brain-Derived Neurotrophic Factor: A Therapeutic Target for Depression

Emily Chiang & Nella Delva

Abstract

As depression rates increase among Americans, neuroscientists seek for more efficient targets for treating major depressive disorder (MDD). Brain-derived neurotrophic factor (BDNF), a neurotrophic protein, has been shown to be associated with the development of neuropsychological disorders such as MDD. Thus, targeting BDNF mechanisms through antidepressants, physical exercise, and gene therapy, in search of effective treatments for depression seem probable.

Why Target BDNF?

Major depressive disorder (MDD) affects more than 300 million people worldwide, with increasing numbers in the past decade. MDD encompasses a variety of adverse effects, including feelings of hopelessness, changes in appetite, and in severe cases, intense thoughts of suicide. Despite these debilitating consequences, only about half of people in the United States suffering from MDD receive effective treatment [1]. In fact, government health budgets allocate a mere 3% to mental health resources. Although the Diagnostic and Statistical Manual of Mental Disorders outlines the various requirements for an MDD diagnosis, the process of diagnosis relies heavily on patient self-report and subjective clinical evaluations.

Since the external, symptomatic diagnosis of depression is largely generalized, patients often have difficulty receiving the specific treatment necessary to alleviate their symptoms. To combat this, researchers focus on internal, pathophysiological approaches to improve the subclassification of MDD among patients, through the use of biomarkers [2]. Biomarkers are biological molecules that serve as indicators of functional or dysfunctional biological processes [3]. (See Figure 2). Among these are neurotrophins, which are proteins that play a vital role in the development, plasticity, and survival of neurons. More specifically, brain-derived neurotrophic factors (BDNF) are neurotrophins that have proven to significantly contribute to the pathophysiology of MDD [4]. This review seeks to evaluate the process by which BDNF abnormalities affect MDD and analyze the various methods of BDNF-targeted treatment for MDD: antidepressant medication, physical exercise, and more recently, gene therapy.

BDNF Correlates with Neurogenesis and Reduced Depressive-Like Symptoms

The functionality of neurogenesis mechanisms in the brain is an important concept in understanding the etiology of depression. In general, high rates of neurogenesis are associated with reduced symptoms of depression, and, conversely, low rates of neurogenesis are associated with increased symptoms. In a 2013 study by Mateus-Pinheiro et al., rats treated with methylazoxymethanol (MAM), a neurotoxin that inhibits neurogenesis, displayed significantly higher levels of depressive-like behaviors, such as anhedonia (lack of pleasure), higher latency in feeding and escaping, and reduced time in open arms, compared to rats without the neurotoxin. (See Figure 1). This demonstrates that lack of neurogenesis is a key factor in depression.

BDNF and TrkB Interactions Strengthen Neurons

The binding of BDNF ligand to its receptor, tropomyosin receptor kinase B (TrkB), is greatly involved in regulating neuronal activity [6]. BDNF first binds to its high-affinity receptor TrkB on the postsynaptic dendrite and cell body. BDNF and TrkB interactions are found to be important in neuron survival, differentiation, dendritic spine complexity, LTP, and synaptic plasticity [7]. Immunohistochemistry (IHC) is a biomarker technique used in research to help visualize expressions of genes, such as TrkB (in red) and Parvalbumin (in green), an inhibitory neuron.

Val66Met Polymorphism Causes Harmful Effects on BDNF Function

Of the hundreds of known polymorphisms or genetic forms, of the BDNF gene, the two most common polymorphisms in which BDNF exists are the Val and the Met polymorphisms [8]. The Val polymorphism is the wild type, where the amino acid valine is found on codon 66 of the BDNF gene. In the mutant Val66Met polymorphism, which affects approximately 30 percent of the population [9], a methionine amino acid is found on codon 66 [10].

              The Val66Met polymorphism introduces many interferences in the processing of BDNF, in comparison to the Val polymorphism. Like most gene expression processes, the precursor protein proBDNF is first synthesized in the endoplasmic reticulum. It then passes through the Golgi apparatus, where it is cleaved to form mature BDNF (mBDNF). After it passes the Golgi, the mBDNF protein leaves the cell body through secretory vesicles [11]. In the Val66Met polymorphism, however, the proBDNF protein is less likely to pass through the Golgi apparatus. This means that it is less likely to reach secretory vesicles and be secreted from the neuron body. As a result, less BDNF is expressed as ligands, resulting in fewer interactions between BDNF and TrkB, further resulting in decreased synaptic activity and neuroplasticity [12]. (See Figure 3). In addition to reduced BDNF expression, the Val66Met polymorphism also prevents the maturation of BDNF.

ProBDNF Leads to Opposite Effects of Mature BDNF

BDNF is initially synthesized as a precursor protein (proBDNF), which is cleaved by the enzyme furin to produce mature BDNF. ProBDNF ligand binds with the p75 neurotrophin receptor, while mBDNF preferentially binds with the receptor TrkB [13]. ProBDNF-p75NTR binding has been shown to negatively modulate dendritic complexity and spine density in mice. Mice whose p75 neurotrophin receptor genes have been knocked out display greater number of spines, instances of co-localization, and overall complexity, than wild-type mice [14]. This indicates that interactions between the p75 neurotrophin receptor and its ligand, proBDNF, are responsible for reducing cell survival and synaptic plasticity, which in turn increases long-term depression. This view is also supported by Teng et al., who concluded that proBDNF acts as a proapoptotic ligand, meaning that it correlates with the increase of neuronal cell death. The decrease in neuronal plasticity, coupled with the apoptotic effects, proves that the proBDNF mechanism plays a role in inducing harmful symptoms of depression. The Val66Met polymorphism has been shown to hinder the ability of proBDNF to mature into mBDNF, prolonging such deleterious effects of proBDNF-p75NTR interactions [16].

Antidepressants as a BDNF-Targeted Treatment for MDD

Amongst the 17.5 million Americans diagnosed with depression from 2005 to 2016, around 10 million were prescribed some form of antidepressant medication, making antidepressant medication one of the most common treatments for depression [17]. Specifically, selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine are used to prolong the presence of the neurotransmitter serotonin within the synaptic cleft. Aside from its impact on serotonergic pathways within the brain, fluoxetine has been shown to increase BDNF levels and, consequently, the rate of neurogenesis, especially in the dentate gyrus, a key region of the brain where adult neurogenesis occurs [3].

In many preclinical trials, fluoxetine contributes to increased BDNF-TrkB activity and reduced fear [7]. For instance, while fluoxetine is known to increase synaptic plasticity in the adult hippocampus, cortex, and amygdala [18]; in addition, it reverts the neuroplastic connections responsible for remembering fear-inducing stimuli. As a result, fluoxetine-induced plasticity contributes to fear erasure, a system that is mediated by BDNF [19]. These preclinical trials provide a glimpse into the use of fluoxetine in mitigating the symptoms of depression, such as fear and anxiety, through BDNF systems.

Physical Activity as an Inducer for BDNF

According to the CDC, exercise “can improve [one’s] cognitive health—helping [to] think, learn, problem-solve, and enjoy an emotional balance.” One of the mechanisms by which physical activity improves mental health is by increasing BDNF levels. Aerobic exercise generally upregulates BDNF gene expression in the hippocampus [20]. As seen in Figure 4, Sleiman et al.’s study showed that the amount of BDNF gene expression and protein availability in the hippocampus correlates with an increase in exercise. In another study, as the distance run by rats increased, so did the level of BDNF mRNA in the brain [22]. These studies both implicate exercise in increasing BDNF levels.

How can researchers be sure that it is through BDNF mechanisms that physical exercise increases synaptic plasticity in the brain, as opposed to other mechanisms? Vaynman et al. investigated the effects of physical activity on synaptic plasticity in the absence of BDNF by blockading BDNF ligands on TrkB receptors. The results revealed that, without BDNF-TrkB pathways, physical activity had minimal effect on synaptic plasticity when compared to functioning BDNF-TrkB pathways. This ultimately suggests that physical activity alleviates symptoms of MDD only by increasing BDNF levels.

Fluoxetine and physical activity have very similar effects on BDNF regulation and synaptic plasticity. Running and fluoxetine stimulate plasticity of new neurons by increasing neuron spine density and dendritic complexity and increasing short-term synaptic plasticity. When it comes to neurogenesis, fluoxetine has been shown to accelerate the S-phase of the cell cycle in dentate gyrus protogeniture cells, whereas physical activity reduces the cell cycle length in each phase. This means that the process of cell division is catalyzed by exercise, while only the interphase period between cell divisions is accelerated by fluoxetine. Regardless, the overall process of cell division is enhanced by both antidepressants and exercise [24].

Gene Therapy: A Promising Look into the Future

An ongoing clinical trial beginning October 2022 focuses on transporting BDNF genes to specific regions of the brain in patients of Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI). Mark Tuszynski of UC San Diego, the principal investigator, seeks to deliver BDNF genes through a vector known as the adeno-associated virus (AAV2). The trial will measure the cognitive effects of induced BDNF levels on symptoms of AD and MCI. The implications are both to improve AD and MCI and to increase neurogenesis and synaptic plasticity, which can potentially counter symptoms of depression. Marking the first trial of AAV2-BDNF on humans, Tuszynski’s study will pioneer a new and effective approach to treating depressive disorders from a genetic standpoint.

References
[1] World Health Organization. (13/09/2021). Depression. World Health Organization. https://www.who.int/health-topics/depression#tab=tab_ 2. Retrieved: 14/08/2022.	[14] Zagrebelsky, Marta, et al. (26/10/2005). The p75 Neurotrophin Receptor Regatively Modulates Dendrite Complexity and Spine Density in Hippocampal Neurons. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. https://doi.org/10.1523/JNEUROSCI.2492-05.2005. Retrieved: 14/09/2022.
[2] Brand, Sarel J., et al. (05/2015). A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Current Neuropharmacology, 13(3), 324–368. https://doi.org/10.2174/1570159x13666150307004545. Retrieved: 14/08/2022.	[15] Teng, Henry, et al. (01/06/2005). ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75NTR and Sortilin. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. https://doi.org/10.1523/JNEUROSCI.5123-04.2005. Retrieved: 14/09/2022.
[3] Carniel, Bruno Perosa and Neusa Sica da Rocha. (21/10/2021). Brain-Derived Neurotrophic Factor (BDNF) and Inflammatory Markers: Perspectives for the Management of Depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry. https://doi.org/10.1016/j.pnpbp.2020.110151. Retrieved: 14/09/2022.	[16] Duman, Ronald S., et al. (16/01/2016). Synaptic Plasticity and Depression: New Insights From Stress and Rapid-Acting Antidepressants. Nat Med. https://doi.org/10.1038/nm.4050. Retrieved: 21/07/2022.
[4] Pitsillou, Eleni, et al. (14/10/2020). The Cellular and Molecular Basis of Major Depressive Disorder: Towards a Unified Model for Understanding Clinical Depression. Molecular Biology Reports. https://doi.org/10.1007/s11033-019-05129-3. Retrieved: 21/07/2022.	[17] ​​Almohammed, Omar. (20/04/2022). Antidepressants and Health-Related Quality of Life (HRQoL) for Patients With Depression: Analysis of the Medical Expenditure Panel Survey from the United States. PloS One. https://doi.org/10.1371/journal.pone.0265928. Retrieved: 14/08/2022.
[5] Mateus-Pinheiro, A., et al. (15/01/2013). Sustained Remission from Depressive-Like Behavior Depends on Hippocampal Neurogenesis. Translational Psychiatry. https://doi.org/10.1038/tp.2012.141. Retrieved: 14/09/2022.	[18] Popova, Dina, et al. (06/11/2017). Chronic Fluoxetine Administration Enhances Synaptic Plasticity and Increases Functional Dynamics in Hippocampal CA3-CA1 Synapses. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.09.003. Retrieved: 11/10/2022.
[6] Xu, B., et al. (15/09/2000). The Role of Brain-Derived Neurotrophic Factor Receptors in the Mature Hippocampus: Modulation of Long-Term Potentiation Through a Presynaptic Mechanism involving TrkB. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience. https://doi.org/10.1523/JNEUROSCI.20-18-06888.2000. Retrieved: 14/09/2022.	[19] Karpova, Nina N., et al. (20/04/2014). Fear Erasure in Mice Requires Synergy Between Antidepressant Drugs and Extinction Training. Science (New York, N.Y.). https://doi.org/10.1126/science.1214592. Retrieved: 11/10/2022.
[7] Phillips Cristy. (08/08/2017). Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection. Neural Plasticity. https://doi.org/10.1155/2017/7260130. Retrieved: 18/07/2022.	[20] Kim, Kijeong, et al. (01/12/2015). Effects of Treadmill Exercise-Intensity on Short-Term Memory in the Rats Born of the Lipopolysaccharide-Exposed Maternal Rats. Journal of Exercise Rehabilitation. https://doi.org/10.12965/jer.150264. Retrieved: 14/09/2022.
[8] Rostami, Elham, et al. (08/11/2011). BDNF Polymorphism Predicts General Intelligence After Penetrating Traumatic Brain Injury. PloS One. https://doi.org/10.1371/journal.pone.0027389. Retrieved: 14/09/2022.	[21] Sleiman, Sama F., et al. (02/06/2016). Exercise Promotes the Expression of Brain Derived Neurotrophic Factor (BDNF) Through the Action of the Ketone Body β-Hydroxybutyrate. eLife. https://doi.org/10.7554/eLife.15092. Retrieved: 07/10/2022.
[9] Shimizu, Eiji, et al. (01/04/2004) Ethnic Difference of the BDNF 196G/A (Val66Met) Polymorphism Frequencies: The Possibility to Explain Ethnic Mental Traits. Am J Med Genet B Neuropsychiatr Genet. doi: 10.1002/ajmg.b.20118. Retrieved: 14/09/2022.	[22] Zoladz, J. A. and A. Pilc. (10/2010). The Effect of Physical Activity on the Brain Derived Neurotrophic Factor: From Animal to Human Studies. Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society. Retrieved: 14/09/2022.
[10] Park, Chang-hyun, et al. (03/08/2017). The BDNF Val66Met Polymorphism Affects the Vulnerability of the Brain Structural Network. Frontiers in Human Neuroscience. https://doi.org/10.3389/fnhum.2017.00400. Retrieved: 23/09/2022.	[23] ​​Vaynman, Shoshanna, et al. (01/05/2004). Exercise Induces BDNF and Synapsin I to Specific Hippocampal Subfields. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.20077. Retrieved: 14/09/2022.
[11] Bathina, Siresha and Undurti N Das. (11/12/2015). Brain-derived Neurotrophic Factor and Its Clinical Implications. Archives of Medical Science. https://doi.org/10.5114/aoms.2015.56342. Retrieved: 07/08/2022.	[24] Micheli Laura, et al. (01/10/2018). Depression and Adult Neurogenesis: Positive Effects of the Antidepressant Fluoxetine and of Physical Exercise. Brain Res Bull. PMID: 30236533. Retrieved: 17/10/2022.
[12] Finan John D., et al. (2018) The Influence of the Val66Met Polymorphism of Brain-Derived Neurotrophic Factor on Neurological Function after Traumatic Brain Injury. J Alzheimer’s Dis. doi: 10.3233/JAD-180585. Retrieved: 06/08/2022.	[25] Tuszynski, Mark. (10/09/2022). A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment. Retrieved: 17/10/2022.
[13] Mitre, Mariela, et al. (01/01/2017). Neurotrophin Signaling: Novel Insights into Mechanisms and Pathophysiology. Clinical Science. https://doi.org/10.1042/CS20160044. Retrieved: 14/08/2022.